Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | HMGCR | P04035 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30871956 | 1.00 | CYP3A4 (0.56) | CYP3A4NPSR1POLBTAAR1HMGCR | |
| SCHEMBL7827237 | 0.96 | NPSR1 (0.55) | CYP3A4NPSR1POLBTAAR1HMGCR | |
| SCHEMBL11331668 | 0.87 | TAAR1 (0.59) | CYP3A4NPSR1POLBTAAR1STING1 | |
| Butyric Acid SCHEMBL28877004 | 0.86 | HMGCR (0.59) | CYP3A4TAAR1HMGCRSTING1CYP19A1 | |
| SCHEMBL21186320 | 0.85 | CYP3A4 (0.67) | CYP3A4TAAR1HMGCRGLACYP19A1 | |
| SCHEMBL7820588 | 0.84 | SMN1; SMN2 (0.58) | CYP3A4NPSR1POLBTAAR1KMT2A | |
| SCHEMBL14441618 | 0.84 | POLB (0.51) | CYP3A4NPSR1POLBHMGCR | |
| SCHEMBL19953777 | 0.81 | POLB (0.61) | CYP3A4NPSR1POLBHMGCRIMPDH2 | |
| SCHEMBL27834259 | 0.81 | SLC2A1 (0.56) | NPSR1POLBSTING1KMT2AMEN1 | |
| SCHEMBL7193965 | 0.80 | CYP3A4 (0.51) | CYP3A4NPSR1TAAR1HMGCRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995067-B2 | Treatment of Fabry disease | ACADEMIA SINICA (TW) | 2021-05-04 | — | — | US | disclosed |
| US-20190225579-A1 | TREATMENT OF FABRY DISEASE | ACADEMIA SINICA (TW) | 2019-07-25 | — | — | US | disclosed |
| EP-3471736-A1 | TREATMENT OF FABRY DISEASE | Academia Sinica (TW) | 2019-04-24 | — | — | EP | disclosed |
| CN-109641005-A | Treat Fabry disease | 中央研究院 | 2019-04-16 | — | — | CN | disclosed |
| WO-2017222881-A1 | TREATMENT OF FABRY DISEASE | ACADEMIA SINICA (TW) | 2017-12-28 | — | — | WO | disclosed |
| US-8268293-B2 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| EP-1871735-A1 | ANTIOXIDANTS | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871339-A1 | UV PROTECTION | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006111233-A1 | ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006111234-A1 | UV PROTECTION | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| CN-1156443-A | Benzocycloalkene compound, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225579-A1 | TREATMENT OF FABRY DISEASE | GBA2, GBA1, GAA | CYP3A4 4587/4885NPSR1 1914/4885POLB 1672/4885 |
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | CYP3A4 392/4885NPSR1 2684/4885POLB 259/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | CYP3A4 63/4885NPSR1 3626/4885POLB 236/4885 |
| US-10995067-B2 | Treatment of Fabry disease | GBA2, GBA1, GAA | CYP3A4 4587/4885NPSR1 1914/4885POLB 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.